Elipovimab
Elipovimab (formerly known as GS-9722) is a first in class of effector-enhanced
phase 1b clinical testing, designed with the goal of reducing or eliminating the HIV reservoir in patients.[1][2]
References
- ^ "GS-9722: FIRST-IN-CLASS EFFECTOR-ENHANCED BROADLY NEUTRALIZING ANTIBODY FOR HIV CURE". CroiConference.Org.
- ^ "Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys". Gilead.com.